Abstract:Immune checkpoint inhibitors (ICPIS) can greatly improve the overall survival rate of tumor patients with significant efficacy. Currently, ICPIS have been approved for a variety of tumor treatments, bringing hope to many cancer patients. However, at the same time, due to the overactivation of the immune system, it can produce immune-related adverse reactions to all organs of the body. Thyroid related dysfunction is one of the relatively common endocrine adverse events in the treatment of ICPIS. This paper reviewed relevant literature and summarized the clinical characteristics of ICPIS from the perspectives of distribution, action characteristics, epidemiology and pathogenesis. In addition, how to screen high-risk patients in clinical work, as well as the differences and similarities of follow-up monitoring and treatment methods of ICPIS-related thyroid dysfunction in current domestic and foreign guidelines are discussed.
